MedTrace Logo

Drug-drug Interaction Study of SPH3127

NCT05359055 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-07-29

No results posted yet for this study

Summary

A single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in male healthy subjects.

Conditions

  • Drug Drug Interaction

Interventions

DRUG

SPH3127 tablet

100mg once daily on Day 1 and Day 8

DRUG

Itraconazole

200mg once daily from Day 3 to Day10.

DRUG

SPH3127 tablet

200mg once daily on Day 1 and Day 12.

DRUG

Rifampin

600mg once daily from Day 3 to Day13.

Sponsors & Collaborators

  • Shanghai Pharmaceuticals Holding Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Qin Yu · West China Second University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-13
Primary Completion
2022-01-21
Completion
2022-01-21

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05359055 on ClinicalTrials.gov